Vara, the AI-enabled breast cancer detection platform, has raised $8.9 million (€8M) in funding from Smart Family Office (Austria), FJH (Germany), and IBB Ventures. The investment comes as the company expands its successful European operations into emerging markets, with a particular focus on India. The Berlin-based company has established a significant presence in Germany’s National Breast Cancer Screening Program, where its AI…
DeepHealth has announced its acquisition of UK-based Kheiron Medical Technologies, marking a significant consolidation in the AI-powered breast cancer screening space. The acquisition brings together DeepHealth’s Smart Mammo platform with Kheiron’s Mia (Mammography Intelligent Assessment) suite of solutions. The move appears strategically timed as AI continues to gain traction in medical imaging, particularly in mammography where radiologist shortages and increasing screening volumes…
The U.S. Food and Drug Administration (FDA) has approved Genentech’s Itovebi (inavolisib) for the treatment of advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a PIK3CA mutation. Itovebi is to be used in combination with palbociclib (Ibrance) and fulvestrant. This approval is based on results from the Phase III INAVO120 study, which showed that the Itovebi-based…
Midi Health, a virtual care clinic for women 35 and older, has announced the launch of a Survivorship Program. This program aims to provide menopause care for breast cancer survivors and women at high risk for breast cancer. The program was developed and is led by Dr. Mindy Goldman, a Clinical Professor in the Department of OB/GYN at UC San Francisco and…
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali (ribociclib) for a new indication in early breast cancer. This approval marks a significant development in breast cancer treatment, particularly for women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer. The FDA has approved Kisqali in combination with an aromatase inhibitor for adjuvant…
DeepLook Medical, the company behind DL Precise, the first FDA-cleared AI technology designed to detect cancer in dense breast tissue, has announced the successful first close of its Series A funding round. The round was led by Xcellerant Ventures, with additional support from OKG Capital. This funding milestone will support the company’s continued growth and its efforts to enhance cancer detection and…
Oncology diagnostics company PreciseDx has successfully raised $20.7 million in Series B funding. This latest investment, led by Eventide Asset Management, brings the company’s total funding to $31.5 million. Other participants in the round include Labcorp, Quest Diagnostics, and GenHenn Capital Venture. The capital infusion is set to accelerate the commercialization of PreciseDx’s flagship product, PreciseBreast, an AI-powered risk assessment tool for…
Cairn Surgical, a medtech company focused on enhancing the precision of breast cancer surgeries, has successfully closed $4.5 million in Series A2 financing led by Morningside Ventures. The newly acquired funds will be directed towards completing the pivotal U.S. trial of Cairn Surgical’s Breast Cancer Locator (BCL™) System, a novel technology designed to significantly enhance the accuracy of breast-conserving surgeries, commonly known…
